Caladrius Biosciences Inc (NASDAQ:CLBS) - Share price


Stock Report

Caladrius Biosciences Inc CLBS

Last Price
$1.21

Day Change
-0.01|-0.82%

As of 27/09/2021
16:13:50 EDT | USD
Minimum 15 Minutes Delay.

Last Close1.22
Day Range1.19 - 1.23
Mkt Cap-
52-Wk Range1.15 - 4.89
Yield %-
ISINUS1280582032
Volume176,688
P/E-
P/SInfinity
P/CF-1.95

Share Price

Financials
201820192020
More ...
Income Statement
Revenue0.000.000.00
Operating Income-16.99-20.09-19.15
Net Income-16.17-19.36-8.15
Basic EPS-1.67-1.88-0.53
Avg. Diluted Shares Outstanding101015
Balance Sheet
Current Assets44.1125.9735.33
Non Current Assets0.471.180.67
Total Assets44.5827.1536.00
Current Liabilities5.625.983.51
Total Liabilities7.136.603.76
Total Equity37.7320.8232.50
Cash Flow
Operating Cash Flow-19.99-18.88-8.82
Capital Expenditure-0.13--0.02
Free Cash Flow-20.12--8.84

In millions, except "Basic EPS". Currency is USD.

Company Profile

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA).

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Value

Fiscal Year Ends

December

Employees

24
Key Stats
More ...
Price/Earning TTM-1.20
Price/Book0.69
Price/Sales TTMInfinity
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % TTM-Infinity
Net Margin % TTM-Infinity
ROE TTM-30.57
Debt/Equity0.01
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.